Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Subscribe To Our Newsletter & Stay Updated
